Where does Pepex Biomedical, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Pepex Biomedical, Inc. ranks #20,228 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Pepex Biomedical, Inc. hold?

Pepex Biomedical, Inc. holds 14 US utility patents granted between 2015 and 2022, spanning 12 technology areas.

What is Pepex Biomedical, Inc.'s Innovation Score?

Pepex Biomedical, Inc. has an Innovation Score of 31.6 out of 100 (38th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Pepex Biomedical, Inc. focus on?

Pepex Biomedical, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 10 patents, ranking #1,719 of 7,127 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Pepex Biomedical, Inc.'s patent grant rate increasing or decreasing?

Pepex Biomedical, Inc.'s recent grant velocity is -44% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Pepex Biomedical, Inc.'s patents?

Pepex Biomedical, Inc.'s patents average 14.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Pepex Biomedical, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Pepex Biomedical, Inc.

USPTO PatentsView assignee record - 14 granted patents across 12 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Pepex ranks #20,228 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 12 technology areas.

#20,228
of 49,997 US assignees by volume: 38th percentile
by Innovation Score (31.6/100): 14.4
avg claims per patent: -44%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R20228 · US Corporation #20,228 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #20,228/49,997
PHOTO-FINISH PAVmed
CPC-FOCUS A61B · 12 areas
INNOV-THIN 31.6/100
CLAIMS-RICH 14.4 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -44% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: PAVmed Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Pepex’s 31.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (30%) Velocity 1.3 pts (4%) Breadth 12.2 pts (39%) Claim depth 8.7 pts (28%)

Qualcomm Incorporated · highest

85
Pepex Biomedical · this assignee

32
3D Lighting… · lowest

7

What this shows Pepex's Innovation Score is 31.6/100 (38th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Pepex?

Each dot is one of Pepex’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Pepex’s own 14.4 claims/patent is at or below the 16.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Pepex vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Pepex's grants concentrate

Pepex Biomedical, Inc. is a focused PatentsView assignee: 12 CPC subclasses with 71.4% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2019. By volume, Pepex sits between PAVmed Inc. and Petuum, Inc..

Pepex's three-year grant acceleration

Pepex Biomedical, Inc. shows 1 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Pavmed

14
Payfone

14
Peer

14
Penn Elcom

14
Perfect Mobile

14
Performance LAB

14
Personal Genomics

14
Petuum

14
Pepex Biomedical ◀

14

What this shows Pepex holds 14 patents at rank #20,220, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Pepex

By rank, the assignees closest to #20,220 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Pepex's primary technology class.

Pepex's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 38th percentile higher than 38% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Pepex Biomedical, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	21.4%
2016	3	21.4%
2017	2	14.3%
2019	1	7.1%
2020	1	7.1%
2021	3	21.4%
2022	1	7.1%

Which technologies does Pepex Biomedical, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 10

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 10

Y10T - Technical Subjects Covered BY Former US Classification 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 2

B41M - Printing, Duplicating, Marking, OR Copying PROCESSES; Colour Printing, 1

B81C - Processes OR Apparatus Specially Adapted FOR THE Manufacture OR Treatment OF Microstructural Devices OR Systems 1

H05K - Printed CIRCUITS; Casings OR Constructional Details OF Electric APPARATUS; Manufacture OF Assemblages OF Electrical Components 1

H01L - Semiconductor Devices NOT Covered BY Class H10 1

B29L - Indexing Scheme Associated With Subclass B29c, Relating TO Particular Articles 1

B29C - Shaping OR Joining OF PLASTICS; Shaping OF Material IN A Plastic State, NOT Otherwise Provided FOR; After-treatment OF THE Shaped Products, e.g. Repairing 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Pepex Biomedical, Inc.'s patent record in context - here's where to go next.

Pepex Biomedical, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 71.4% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #20,228 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Pepex Biomedical, Inc. against PAVmed Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 31.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.